Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
102.02
+0.47 (0.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuroscience | 2.66B | 2.63B | 2.64B | 2.71B | 2.76B | 2.80B | 2.80B | 2.76B | ||||||||
| Neuroscience Growth | -3.68% | -5.92% | -5.85% | -1.92% | 1.99% | 5.89% | 10.92% | 18.22% | ||||||||
| Oncology | 1.09B | 1.07B | 1.04B | 1.02B | 965.36M | 928.30M | 905.92M | 873.84M | ||||||||
| Oncology Growth | 13.26% | 15.16% | 15.23% | 16.18% | 12.64% | 13.42% | 20.40% | 19.08% |
Oncology Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rylaze Enrylaze | 411.11M | 417.19M | 411.05M | 394.23M | 373.45M | 342.11M | 313.37M | 281.66M | ||||||||
| Rylaze Enrylaze Growth | 10.08% | 21.95% | 31.17% | 39.97% | 40.58% | 60.76% | 124.07% | 228.93% | ||||||||
| Zepzelca | 316.00M | 308.15M | 297.45M | 289.53M | 287.49M | 279.82M | 277.76M | 269.91M | ||||||||
| Zepzelca Growth | 9.92% | 10.13% | 7.09% | 7.27% | 9.40% | 5.92% | 10.30% | 9.36% | ||||||||
| Defitellio Defibtrotide | 210.00M | 191.91M | 192.60M | 184.00M | 173.57M | 175.29M | 183.88M | 194.29M | ||||||||
| Defitellio Defibtrotide Growth | 20.99% | 9.48% | 4.74% | -5.30% | -11.51% | -14.24% | -7.04% | -1.84% | ||||||||
| Vyxeos | 156.26M | 151.77M | 142.82M | 147.50M | 130.85M | 131.09M | 130.92M | 127.98M | ||||||||
| Vyxeos Growth | 19.42% | 15.78% | 9.09% | 15.25% | -1.23% | -4.38% | -2.78% | -4.54% |
Neroscience Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xywav | 1.41B | 1.35B | 1.31B | 1.27B | 1.22B | 1.14B | 1.05B | 958.43M | ||||||||
| Xywav Growth | 15.77% | 18.46% | 24.80% | 32.82% | 41.60% | 50.85% | 62.56% | 79.05% | ||||||||
| Epidiolex | 938.00M | 900.15M | 855.28M | 845.47M | 811.84M | 794.35M | 767.41M | 736.40M | ||||||||
| Epidiolex Growth | 15.54% | 13.32% | 11.45% | 14.81% | 12.26% | 15.57% | 23.47% | 58.83% | ||||||||
| Xyrem | 291.25M | 358.24M | 455.83M | 569.73M | 710.51M | 841.43M | 951.09M | 1.02B | ||||||||
| Xyrem Growth | -59.01% | -57.42% | -52.07% | -44.17% | -33.08% | -24.40% | -19.25% | -19.38% | ||||||||
| Sativex | 18.84M | 18.88M | 15.31M | 19.67M | 19.25M | 17.85M | 19.18M | 16.83M | ||||||||
| Sativex Growth | -2.13% | 5.81% | -20.21% | 16.90% | 14.92% | -9.09% | 9.93% | 32.41% |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.